GlassScriptPhysician profile
Marc T Claydon
NPI 1447601802
$9,270.45
in general payments reported to CMS, 2019-2025
14 companies · $1,095 in 2025
The $1,095 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,156 · 2020: $20.19 · 2021: $1,238 · 2022: $3,574 · 2023: $996 · 2024: $191 · 2025: $1,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,181 · Food and Beverage: $1,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,180.86 |
| Food and Beverage | $1,100.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $3,737.22 | 2022-2025 | |
| Pinnacle, INC | $1,906.16 | 2019 | |
| Sequoia Surgical, INC. | $1,238.00 | 2021 | |
| Stryker Corporation | $1,118.14 | 2019-2024 | Augment Injectable, Variax, Hoffmann |
| Evolution Surgical, INC | $701.06 | 2022-2025 | |
| Smith+Nephew, INC. | $179.54 | 2022-2023 | Cadence |
| Abbvie INC. | $127.19 | 2024-2025 | |
| Abbott Laboratories | $117.00 | 2025 | Diamondback Peripheral |
| Stimwave Technologies Incorporated | $41.20 | 2019 | |
| Novo Nordisk INC | $23.61 | 2019 | |
| Zimmer Biomet Holdings, INC. | $22.59 | 2019 | |
| Paratek Pharmaceuticals, INC. | $20.19 | 2020 | |
| Kerecis Limited | $19.75 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Kci USA, INC. | $18.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Claydon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.